Company Presentation • 29 Mar 2023 15:30
Q4 2022
Company Presentation • 20 Sep 2023 16:00
Q2 2023
Company Presentation • 30 Oct 2023 17:00
Q3 2023
Company Presentation • 27 Mar 2024 17:00
Q4 2023
Company Presentation • 26 Apr 2024 16:00
𝛼SK or SearchENTITY
Remegen (688331 CH)
Remegen (688331 CH)
105
Analysis
Health Care • China
RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.
morex